¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"red cell adherence phenomenon"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • recruitment phenomenon
    Á¡ÁõÇö»ó, º¸ÃæÇö»ó, ´©°¡Çö»ó
  • reentry phenomenon
    Àçµ¹ÀÔÇö»ó
  • reversed crossing phenomenon
    ¿ª±³Â÷Çö»ó
  • revolving door phenomenon
    ȸÀü¹®Çö»ó
  • staircase phenomenon
    °è´ÜÇö»ó
  • sunset phenomenon
    ÇØ³ÑÀÌÇö»ó, ÀϸôÇö»ó
  • switch phenomenon
    ½ºÀ§Ä¡Çö»ó
  • vital phenomenon
    »ý¸íÇö»ó
  • acantholytic cell
    °¡½Ã¼¼Æ÷ºÐ¸®¼¼Æ÷
  • angioimmunoblastic T-cell lymphoma
    Ç÷°ü¸é¿ª¸ð±¸T¼¼Æ÷¸²ÇÁÁ¾
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
  • sickle cell trait
    ³´¼¼Æ÷¼ÒÁú, ³´ÀûÇ÷±¸Çü¼º¼ÒÁú
  • packed cell volume
    ÃæÀü¼¼Æ÷¿ëÀû, ³óÃ༼Æ÷¿ëÀû
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • recruitment phenomenon
    Á¡ÁõÇö»ó, ´©°¡Çö»ó, º¸ÃæÇö»ó
  • reentry phenomenon
    ȸ±ÍÇö»ó
  • reversed crossing phenomenon
    ¿ª±³Â÷Çö»ó
  • revolving door phenomenon
    ȸÀü¹®Çö»ó
  • staircase phenomenon
    °è´ÜÇö»ó
  • sunset phenomenon
    ÇØ³ÑÀÌÇö»ó, ÀϸôÇö»ó
  • switch phenomenon
    ½ºÀ§Ä¡Çö»ó
  • threshold phenomenon
    ¹®ÅΰªÇö»ó, ¿ªÄ¡Çö»ó
  • transitional phenomenon
    ÀϽÃÀûÇö»ó
  • vital phenomenon
    »ý¸íÇö»ó
  • acantholytic cell
    °¡½Ã¼¼Æ÷ÇØ¸®¼¼Æ÷
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • acidophilic cell
    È£»ê¼º¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷
  • acinic cell carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • phi phenomenon
    ÆÄÀÌÇö»ó
  • phrenic phenomenon
    Ⱦ°Ý¸·Çö»ó(¡­úÞßÚ).
  • pronation phenomenon
    ȸ³»Çö»ó(üÞÒ® úÞßÚ).
  • raynaud s phenomenon
    ·¹À̳ëÇö»ó(¡­úÞßÚ)
  • reclotting phenomenon
    ÀçÀÀ°íÇö»ó(î¢ëêͳúÞßÚ).
  • recruitment phenomenon
    Á¡ÁõÇö»ó(ïÂñòúÞßÚ), ´©°¡Çö»ó(׫ʥúÞßÚ), º¸ÃæÇö»ó( ÜÍõöúÞßÚ).
  • recruitment phenomenon
    ´©°¡Çö»ó
  • rejection phenomenon
    °ÅÀýÇö»ó(ËÞï¾úÞßÚ).
  • rejection phenomenon
    °ÅÀýÇö»ó(ËÞï¾úÞßÚ).
  • release phenomenon
    À¯¸®Çö»ó.
  • NK cell [=natural killer cell]
    ÀÚ¿¬»ì»ó¼¼Æ÷
  • alpha cell glucagon cell
    ¾ËÆÄ¼¼Æ÷ ±Û·çÄ«°ï¼¼Æ÷
  • quiescent cell, Q cell
    Á¤Áö¼¼Æ÷
  • Congo red stain
    Äá°í·¹µå ¿°»ö(æøßä)
  • Congo red test
    Äá°íÀû½ÃÇè.»ýÈ­Äá°í·¹µå½ÃÇè.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • entopic phenomenon
    ³»½ÃÇö»ó
  • entotic phenomenon
    À̳»Çö»ó
  • entry phenomenon
    ÁøÀÔ Çö»ó
  • entry slice phenomenon
    À¯ÀÔ ´Ü¸é Çö»ó
  • escape phenomenon
    ÀÌÅ»Çö»ó.
  • escape phenomenon
    ÀÌÅ»(ìÆ÷­)Çö»ó(úÞßÚ)
  • flare phenomenon
    Àå°³ Çö»ó
  • great toe phenomenon
    ¸ðÁ·Áö Çö»ó(Ù½ðëò¿úÞßÚ), Á·¹«Áö Çö»ó.
  • hayflick phenomenon
    °ÇÃÊÅÐÀÌÇö»ó
  • hip flexion phenomenon
    °í±¼ Çö»ó(ÍÆÏÝúÞßÚ), °í±¼ ¹Ý»ç(¡­ÚãÞÒ).
  • iceberg phenomenon
    ºù»ê Çö»ó
  • identification phenomenon
    µ¿ÀϽà Çö»ó
  • immune phenomenon
    ¸é¿ªÇö»ó.
  • interference phenomenon
    °£¼·Çö»ó
  • interference phenomenon
    °£¼·Çö»ó(ÊÎàïúÞßÚ).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • Secretory synovial cell
    ºÐºñÀ±È°¼¼Æ÷
    [¿¾ ¿ë¾î] Ȱ¸·ºÐºñ¼¼Æ÷
  • Mast cell
    ºñ¸¸¼¼Æ÷
    [¿¾ ¿ë¾î] ºñ¸¸¼¼Æ÷
  • Intercalated epithelial cell
    »çÀÌ»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Áß°£Ãþ»óÇǼ¼Æ÷
  • Interstitial cell
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
  • Epithelial reticular cell
    »óÇǼ¼¸Á¼¼Æ÷
    [¿¾ ¿ë¾î] »óÇǼº¼¼¸Á¼¼Æ÷
  • Pigment epithelial cell
    »ö¼Ò»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] »ö¼Ò»óÇǼ¼Æ÷
  • Glandular cell
    »ù¼¼Æ÷
    [¿¾ ¿ë¾î] ¼±¼¼Æ÷
  • Ciliated ependymal cell
    ¼¶¸ð³ú½Ç¸·¼¼Æ÷
    [¿¾ ¿ë¾î] ¼¶¸ð»óÀǼ¼Æ÷
  • Ciliated epithelial cell
    ¼¶¸ð»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¼¶¸ð»óÇǼ¼Æ÷
  • Ciliated cell
    ¼¶¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ¼¶¸ð¼¼Æ÷
  • Apex of cell
    ¼¼Æ÷²À´ë±â
    [¿¾ ¿ë¾î] ¼¼Æ÷÷
  • Cell membrane
    ¼¼Æ÷¸·
    [¿¾ ¿ë¾î] ¼¼Æ÷¸·
  • Base of cell
    ¼¼Æ÷¹Ù´Ú
    [¿¾ ¿ë¾î] ¼¼Æ÷Àú
  • Cell organelles
    ¼¼Æ÷¼Ò±â°ü
    [¿¾ ¿ë¾î] ¼¼Æ÷¼Ò±â°ü
  • Axis of cell
    ¼¼Æ÷Ãà
    [¿¾ ¿ë¾î] ¼¼Æ÷Ãà
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • null cell
    ¹«Ç¥Áö¼¼Æ÷(Ùíøúò½á¬øà)
  • permanent cell strain
    ¿µ±¸¼¼Æ÷ÁÖ(çµÎùá¬øàñ»)
  • permissive cell
    Çã¿ë ¼¼Æ÷(úÉé»á¬øà)
  • photoelectric cell
    ±¤ÀüÁö(ÎÃï³ò®)
  • photovoltaic cell
    ±¤ÀüÁö (ÎÃï³ò®)
  • plaque forming cell
    ÇöóÅ© Çü¼º ¼¼Æ÷(û¡à÷á¬øà)
  • plasma cell
    ÇüÁú¼¼Æ÷(û¡òõá¬øà)
  • primed cell
    °¨ÀÛ¼¼Æ÷(ÊïíÂá¬øà)
  • productive cell
    »ý»ê ¼¼Æ÷(ßæß§á¬øà)
  • regulated secretory cell
    ÇÇÁ¶Àý(ù¬ðàï½) ºÐºñ¼¼Æ÷(ÝÂÝôá¬øà)
  • resting cell
    È޽O÷(ýÌãÓá¬øà)
  • restrictive cell
    Á¦ÇÑ ¼¼Æ÷(á¬øà)
  • sector cell
    ¼½ÅͽÇ(ãø)
  • separation cell
    ºÐ¸®½Ç(ÝÂ×îãø)
  • sickle cell
    ³´¼¼Æ÷(á¬øà)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
CRST Syndrome   1. Calcinosis
  2. Raynaud's Phenomenon
  3. Sclerodactyly
...
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
VF   1) Ventricular Fibrillation
    ? Tx of Ventricular Fibrillation ...
B-G Bordet-Gengou [agar, bacillus, phenomenon]
CREST calcinosis, Raynaud phenomenon, esophageal involvement, sclerodactyly, and telangiectasia [syndrome]...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
RCA Red cell aggregation
RCC Red cell concentrates
RCD Red cell deformability
RDW Red cell distribution width
RFR Red cell filtration rate
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Alzheimers cell
    ¾ËÂêÇÏÀÌ¸Ó ¼¼Æ÷
  • amplifying cell
    Áõ½Ä ¼¼Æ÷
  • angiotropic intravascular large cell lymphoma
    Ç÷°ü ¿µ¾ç¼º Ç÷°ü³» ´ë¼¼Æ÷ ¸²ÇÁÁ¾
  • anterior horn cell
    Àü°¢ ¼¼Æ÷
  • antibody dependent cell mediated cytotoxicity
    Ç×ü ÀÇÁ¸ ¼¼Æ÷ ¸Å°³ ¼¼Æ÷ µ¶¼º, Ç×ü ÀÇÁ¸¼º ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
  • antigen binding cell
    Ç׿ø °áÇÕ ¼¼Æ÷
    Ç׿ø¿¡ ´ëÇÑ Æ¯ÀÌÀûÀÎ °áÇձ⸦ ¼¼Æ÷ Ç¥¸é¿¡ °¡Áö°í ÀÖÀ¸¸ç Ç׿øÀ» ¼¼Æ÷ Ç¥¸é¿¡ °áÇÕ½ÃŰ´Â ´É·ÂÀ» °¡Áø ¼¼Æ÷. B ¼¼Æ÷ ¹× ÀϺÎÀÇ T ¼¼Æ÷°¡ Ç׿ø °áÇÕ ¼¼Æ÷¿¡ ÇØ´çµÈ´Ù. À̵éÀÇ ¸²ÇÁ±¸ÀÇ ¼¼Æ÷ Ç¥¸é¿¡ Ç׿øÀÌ °áÇյǾî ÀÖ´Â »óŸ¦ °¢Á¾ ¹æ¹ýÀ¸·Î È®ÀÎÇÒ ¼ö ÀÖ´Ù. Ç׿øÀ» ¹æ»ç¼º ¹°Áú·Î Ç¥ÁöÇØ µÎ°í autoradiogra
  • antitumor k cell
    Ç×Á¾¾ç k ¼¼Æ÷
  • anucleate cell
    ¹«ÇÙ ¼¼Æ÷
    ÇüÅÂÀûÀ¸·Î ºÐÈ­ÇÑ ±¸Á¶·Î¼­ÀÇ ÇÙÀ» °¡ÁöÁö ¾Ê´Â ¼¼Æ÷. ¼¼±ÕÀ̳ª ³²Á¶·ù¿¡¼­´Â ÇüÅÂÀûÀ¸·Î ¶Ñ·ÇÇÏ°Ô ºÐÈ­ÇÑ ÇÙÀÌ ¾ø´Ù. ÀÌ·¯ÇÑ ¼¼Æ÷¸¦ ÇÁ·ÎÄ«¸®¿ÀÆ®
  • APUD cell
    APUD ¼¼Æ÷
    amine
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º ±âÀú¼¼Æ÷ ¾Ï
  • B cell
    B ¼¼Æ÷
    °ñ¼ö¿¡¼­ Çü¼ºµÈ ¸²ÇÁ±¸, ÇüÁú ¼¼Æ÷·Î ÀüȯµÇ¾î Ç×ü¸¦ »ý¼º. ÃéÀåÀÇ ¶û°Ô¸£Çѽº ¼¶¿¡ ÀÖ´Â 4Á¾·ùÀÇ ¼¼Æ÷ Áß Çϳª·Î¼­ Àν¶¸°À» ºÐºñÇÑ´Ù.
  • B cell clone
    B ¼¼Æ÷ Ŭ·Ð
    Ŭ·ÐÀ̶õ ´ÜÀÏÀÇ ¼¼Æ÷¸¦ Á¶»óÀ¸·Î ÇÏ´Â 1±ºÀÇ ¼¼Æ÷¸¦ ¸»ÇÑ´Ù. µû¶ó¼­ B ¼¼Æ÷ Ŭ·ÐÀº ´ÜÀÏÀÇ B ¼¼Æ÷°¡ ºÐ¿­, Áõ½ÄÇÏ¿© Çü¼ºÇÑ B ¼¼Æ÷ Áý´ÜÀ» ¸»ÇÑ´Ù. ÀÌ °æ¿ì µ¿ÀÏÇÑ ¸é¿ª ±Û·ÎºÒ¸° V À¯ÀüÀÚ¸¦ ¹ßÇöÇϰí ÀÖ´Â B ¼¼Æ÷·Î »ý°¢ÇÒ ¼ö ÀÖ´Ù. Á¤»óÀÇ B¼¼Æ÷´Â ¾Æ´ÏÁö¸¸ ¼¼Æ÷À¶ÇÕ¹ýÀ¸·Î ¾ò¾îÁø B ¼¼Æ÷ À¶ÇÕÁ¾µµ ¶Ç B¼¼Æ÷ Ŭ·ÐÀ̶ó°í ºÒ¸®¿ì´Â ¼ö°¡ ÀÖ´Ù.
  • B cell growth factor
    B ¼¼Æ÷ ¼ºÀå ÀÎÀÚ, B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ
    B ¼¼Æ÷°¡ ÇüÁú ¼¼Æ÷·Î ºÐÈ­ÇÏ´Â °úÁ¤Àº Å©°Ô 2´Ü°è·Î ³ª´©¾îÁø´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ¿ì¼± Áõ½ÄÇϰí, ±× ÈÄ¿¡ Ç×ü¸¦ »ý»êÇÏ¿© ºÐºñÇÏ´Â ÇüÁú ¼¼Æ÷·Î ºÐÈ­¸¦ ¿Ï¼öÇÑ´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ±× ÀÚÁ¦¸¸À¸·Î´Â Áõ½ÄÇÏÁö ¸øÇϰí T¼¼Æ÷ À¯·¡ÀÇ B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ³ª Ž½Ä ¼¼Æ÷ À¯·¡ ÀÎÀÚ IL-1ÀÇ ÀÚ±ØÀÌ Ãß°¡µÇ¾î Áõ½ÄÀ» ½ÃÀÛÇÑ´Ù. B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ´Â Á¤»óÀÇ T¼¼Æ÷¸¦
  • B cell lymphoma
    B ¼¼Æ÷ ¸²ÇÁÁ¾
    ¾Ç¼º ¸²ÇÁÁ¾ Áß¿¡¼­ ¥ì¼â, DR Ç׿ø, Leu-10ÀÇ B ¸²ÇÁ±¸ Ç¥½ÃÀÚ°¡ Áõ¸íµÈ ¸²ÇÁÁ¾ÀÌ´Ù. Áõ¸íµÈ Ç¥½ÃÀÚ´Â °³°³ÀÇ Áõ·Ê¿¡ µû¶ó ´Ù¸£°í ¥ì+, DR+ Leu-10+ÀÇ ÀüÇüÀûÀÎ ¿¹·ÎºÎÅÍ DR ³»Áö Leu-10¸¸ÀÌ ¾ç¼ºÀÎ Áõ·Ê¿¡ À̸£±â±îÁö ±× º¯È­´Â ´Ù¾çÇÏ´Ù. ÇüÅÂÀûÀÎ ºÐ·ù¿¡ ÀÇÇÑ °áÀý¼º ¸²ÇÁÁ¾, ¸²ÇÁÇüÁú ¼¼Æ÷¼º ¸²ÇÁÁ¾, ¹èÁ᫐ ¼¼Æ÷¿¡¼­ À¯·¡ÇÏ´Â ¸²ÇÁÁ¾, Burkitt ¸²ÇÁÁ¾ µîÀÌ B¼¼Æ÷ ¸²ÇÁÁ¾¿¡ ¼ÓÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
concentrated human red blood corpuscle Corpuscle prepared from one or more preparations of whole human blood which are not more than 14 days old and each of which has already been directly matched with the blood of the intended recipient.
(05 Mar 2000)
Congolian red fever An acute infectious disease with fever, headache, and rash, all quite similar to, but milder than, epidemic typhus, caused by a related microoganism, rickettsia typhi (mooseri), transmitted to humans by rat fleas (xenopsylla cheopis). The animal reservoir includes rats, mice and other rodents. Murine typhus occurs sporadically worldwide but is more prevalent in congested rat-infested urban areas. Also known as endemic typhus, rat-flea typhus; urban typhus of malaya).
(12 Dec 1998)
congo red <chemical> An odourless, dark red or reddish brown powder which decomposes on exposure to acid fumes. It is used as a diagnostic aid in amyloidosis, and has been used as an antihemolytic and detoxicant.
Pharmacological action: dyes.
Chemical name: 1-Naphthalenesulfonic acid, 3,3'-((1,1'-biphenyl)-4,4'-diylbis(azo))bis(4-amino-, disodium salt
(12 Dec 1998)
cresol red <chemical> A reddish-brown powder which can be dissolved in water or alcohol that has the chemical formula of C21H18O5S. The dissolved compound has different colours depending on the pH, when the pH is 7.2 it is yellow, when the pH is 8.8 it is red, and when the pH is 2-3 it is orangish. As a result, it is used as an acid-base indicator. It is also used as a stain in the study of histology.
(09 Oct 1997)
scarlet red O-Tolylazo-o-tolylazo-beta-naphthol. An azo dye; a dark, brownish red powder, soluble in oils, fats, and chloroform, but insoluble in water; used in medicine as a vulnerary, in histology to stain fat in tissue sections and basic proteins at high pH, and in immunoelectrophoresis.
Synonym: Biebrich scarlet red, medicinal scarlet red, scharlach red, Sudan IV.
(05 Mar 2000)
scarlet red sulfonate An azo dye that has been used to stimulate healing of chronic superficial wounds and ulcers.
(05 Mar 2000)
scharlach red O-Tolylazo-o-tolylazo-beta-naphthol. An azo dye; a dark, brownish red powder, soluble in oils, fats, and chloroform, but insoluble in water; used in medicine as a vulnerary, in histology to stain fat in tissue sections and basic proteins at high pH, and in immunoelectrophoresis.
Synonym: Biebrich scarlet red, medicinal scarlet red, scharlach red, Sudan IV.
(05 Mar 2000)
neutral red <chemical> 3-amino-7-dimethylamino-2-methylphenazine hydrochloride. A vital dye used as an indicator and biological stain. Various adverse effects have been observed in biological systems.
Pharmacological action: dyes, indicators and reagents.
Chemical name: 2,8-Phenazinediamine, N8,N8,3-trimethyl-, monohydrochloride
(12 Dec 1998)
Sudan red III A red stain, (C6H5)N==N(C6H4)N==N(C10H6)OH, used for neutral fat in histologic technique; it also stains the fatty envelope of the tubercle bacillus.
Synonym: Sudan red III.
(05 Mar 2000)
Darrow red A basic oxazin dye, C18H14N3O2Cl, used as a substitute for cresyl violet acetate in the staining of Nissl substance.
Origin: Mary A. Darrow, U.S. Stain technologist, 1894-1973
(05 Mar 2000)
quinaldine red A styrene-quinolinium iodide; used as a pH indicator (turns red at pH 3.2) in a 1% ethanol solution.
(05 Mar 2000)
International Committee of the Red Cross A neutral Swiss organization serving as an intermediary between contending forces in armed conflict, in civil war, or internal strife, to help victims receive protection and other humanitarian assistance under the Geneva Conventions in accordance with the fundamental principles of the Red Cross.
(05 Mar 2000)
oil red O 1-8-[4-(Dimethylphenylazo)dimethylphenylazo]-2-naphthalenol;a weakly acid diazo oil-soluble dye, used in histologic demonstration of neutral fats.
(05 Mar 2000)
tanned red cells Erythrocytes subjected to mild treatment with chemicals such as tannic acid so that they adsorb onto their surface soluble antigens; used in haemagglutination tests.
(05 Mar 2000)
Tay's cherry-red spot The ophthalmoscopic appearance of the normal choroid beneath the fovea centralis, appearing as a red spot surrounded by white retinal oedema in central artery closure or lipid infiltration in sphingolipidosis.
Synonym: Tay's cherry-red spot.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • Red Power
    ·¹µåÆÄ¿ö(¾Æ¸Þ¸®Ä­ Àεð¾ðÀÇ ¹®È­Àû.Á¤Ä¡Àû ¿îµ¿ÀÇ ½½·Î°Ç)
  • Red River
    ·¹µå ¸®¹ö(¹Ì±¹ Texas,Oklahoma µÎ ÁÖÀÇ °æ°è¸¦ Èê·¯ Mississippi°­À¸·Î ÇÕ·ù)
  • Red Sea
    È«ÇØ
  • Red Square
    (¸ð½ºÅ©¹ÙÀÇ)ºÓÀº ±¤Àå
  • Red Star
    Àû¼º´Ü(±¹Á¦Àû µ¿¹° ¾ÖÈ£ ´Üü);ºÓÀº º°(¼Ò·Ã ±¹¹æºÎ ±â°üÁö)
  • Red Terror
    °øÆ÷½Ã´ë;(ÀϹÝÀûÀ¸·Î)Àû»öÅ×·¯
  • Rhode Island Red(White)
    ·Îµå ¾ÆÀÏ·£µå ·¹µå(È­ÀÌÆ®)(±êÅÐÀÌ Àû°¥»ö(¼ø¹é»ö)ÀÇ ³­À° °â¿ëÀÇ ¹Ì±¹ ´ß)
  • chrome red
    Å©·Ò·¹µå(Àû»ö ¾È·á)
  • claret red
    £Àº ÀÚÈ«»ö
  • copper red
    Àûµ¿±¤
  • dago red
    °ª½Ñ ¼ú;(¾ËÄÚ¿Ã Áßµ¶ÀÚ°¡ »óÀ½ÇÏ´Â)ÀúÁúÀÇ ÀûÆ÷µµÁÖ
  • favo(u)red
    È£ÀǸ¦(È£°¨À»)»ç°í ÀÖ´Â;ÇýÅÃÀ» ¹Þ°í ÀÖ´Â;Ư¼º.Àç´É µîÀÌ ÀÖ´Â
  • poppy red
    ȲÀû»ö 
  • red
    ºÓÀº;»¡°£;»¡°£»öÀÇ;Àû»öÀÇ;(ÅÐ.ÇǺΠµîÀÌ)ºÓÀº;(³ë¿°.ºÎ²ô·³ µîÀ¸·Î)»¡°³Áø;ÇÇ¿¡ ¹°µç;Ç͹߼±;ºÒŸ´Â µíÇÑ;°Ý½ÉÇÑ(ÀüÀï);ºÓÀº;°ú°ÝÇÑ;Çõ¸íÀûÀÎ;ÀûÈ­µÈ;»¡°»ÀÌÀÇ;°ø»êÁÖÀÇÀÇ;ºÏ±ØÀ» °¡¸®Å°´Â;ºÏ±ØÀÇ;¿µ·ÉÀÇ(Áöµµ¿¡¼­);»¡°­;»¡°£ »ö;Àû»ö;»¡°£ ±×¸²¹°°¨(¾È·á.µµ·á.¿°·á);»¡°£
  • red admiral
    (ºÏ¹Ì.À¯·´»ê)¸ÚÀïÀÌ·ùÀÇ ³ªºñ 
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á